UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                             ----------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                              --------------------

        Date of report (Date of earliest event reported): April 28, 2006

                            Applied DNA Sciences, Inc
               (Exact Name of Registrant as Specified in Charter)


           Nevada                   002-90539                  59-2262718
      (State or Other        (Commission File Number)        (IRS Employer
       Jurisdiction                                       Identification No.)
     of Incorporation)


                       25 Health Sciences Drive, Suite 113
                           Stony Brook, New York 11790
               (Address of Principal Executive Offices) (Zip Code)

                                  631-444-6861
              (Registrant's telephone number, including area code)

                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2 below):

|_|   Written communications pursuant to Rule 425 under the Securities Act
      (17 CFR 230.425)

|_|   Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d- 2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e- 4(c))






Item 8.01  Other Events.

Matter Voluntarily Reported to the Securities and Exchange Commission

      Applied DNA Sciences,  Inc. (the "Company")  previously  disclosed that it
was investigating the circumstances  surrounding  certain issuances of shares to
employees  and  consultants  in 2005.  The  Company  has engaged its new outside
counsel to conduct this investigation. The Company has voluntarily reported it's
current  findings  from  the   investigation  to  the  Securities  and  Exchange
Commission  (the  "SEC"),  and it has  agreed to  provide  the SEC with  further
information  arising  from the  investigation.  The  Company  believes  that the
issuance of 8,000,000  shares to employees in July 2005 was  effectuated by both
the Company's  former  President and it's former Chief  Financial  Officer/Chief
Operating  Officer  without  approval of the board of  directors.  These  former
officers received a total of 3,000,000 of these shares. In addition,  it appears
that the 8,000,000 shares issued in July 2005, as well as an additional  550,000
shares issued to employees and  consultants in March,  May and August 2005, were
improperly issued without a restrictive legend stating that the shares could not
be resold  legally  except in  compliance  with the  Securities  Act of 1933, as
amended. The Company's investigation is continuing. The members of the Company's
management who  effectuated  the stock  issuances that are being examined in the
investigation no longer work for the Company.  The Company believes it may incur
significant costs and expenses in continuing this investigation.


Certain Relationships and Related Transactions

      As the Company has previously disclosed,  on November 3, 2005, the Company
issued and sold a promissory note in the principal  amount of $550,000 to Allied
International  Fund, Inc.  ("Allied").  Allied in turn financed a portion of its
making  of this loan by  borrowing  $450,000  from  certain  persons,  including
$100,000 from James A. Hayward,  a director and the Chief  Executive  Officer of
the Company.  The terms of the  promissory  note provided that the Company issue
upon the  funding  of the note  warrants  to  purchase  5,000,000  shares of the
Company's  common  stock at an  exercise  price of $0.50  per  share to  certain
persons  designated  by Allied.  On  November 9, 2005,  the Company  issued nine
warrants to Allied and eight other persons to purchase an aggregate of 5,500,000
shares of the  Company's  common stock at an exercise  price of $0.50 per share.
These warrants  included a warrant to purchase  1,100,000 shares that was issued
to James A. Hayward,  a director and the Chief Executive Officer of the Company.
Additionally,  the  Company  paid  $55,000  in cash to VC Arjent,  Ltd.  for its
services as the placement  agent with respect to this  placement.  All principal
and  accrued  but unpaid  interest  under the  promissory  note was paid in full
shortly  after the  closing  of and from the  proceeds  of a  private  placement
completed by the Company on March 8, 2006.

      On March 29, 2006 and April 13, 2006, the Company borrowed $200,000 in the
aggregate,  at a rate of 7.5%  per  annum,  from  BioCogent,  Ltd.,  a New  York
corporation  ("BioCogent")  whose President and Chief Executive Officer and sole
stockholder is James A. Hayward,  a director and the Chief Executive  Officer of
the  Company.  These loans are due and payable  upon the earlier to occur of (1)
the close of business on June 30,  2006,  or (2) the closing of the issuance and
sale by the Company of its securities  for gross proceeds of at least  $250,000.
The proceeds from the loans will be used for general corporate purposes.


Litigation

      The Company  previously  disclosed that it had filed an action on April 4,
2006, against defendants Paul Reep, Adrian Butash, John Barnett,  Chanty Cheang,
Jaime Cardona,  and Angela  Wiggins in the United States  District Court for the
Central District of California (Applied DNA Sciences,  Inc. v. Paul Reep, Adrian
Butash, John Barnett, Chanty Cheang, Jaime Cardona, and Angela Wiggins, Case No.
CV06-2027  RGK).  In this  matter  the  Company  has  asked  the court to make a
judicial  determination  that an agreement,  which the Company did not authorize



and which is the basis of previously disclosed litigation against the Company by
Paul Reep, a former  employee of the  Company,  and a new action filed by former
employees of the Company as set forth in the  subsequent  paragraph,  is invalid
and unenforceable. This matter is in its early stages.

      On April 17, 2006,  former employees John D. Barnett,  Jr., Adrian Butash,
Jaime A. Cardona, and Chanty Cheang filed suit against the Company,  Applied DNA
Operations  Management,  Inc., APDN (B.V.I.),  Inc., Peter Brocklesby,  James A.
Hayward, and Jun-Jei Sheu, in Los Angeles County Superior Court (Barnett, et al.
v. Applied DNA  Sciences,  et al., Los Angeles  County  Superior  Court Case No.
BC350904).  The  complaint  alleges  causes of  action  for  breach  of  written
contract,  breach of oral contract,  fraud,  violations of the California  Labor
Code, and wrongful termination and the plaintiffs seek approximately $950,000 in
specified  damages,  plus additional  damages  according to proof, plus fees and
costs.  The  Company  has not been served  with the  complaint  or summons  with
respect to this matter.  The Company disputes all of the allegations and, in the
event that it is served with the summons and  complaint,  intends to  vigorously
defend this action.

      The  Company  previously  disclosed  that  Oceanic  Consulting,  S.A.  had
commenced an action against the Company in the Supreme Court of the State of New
York, County of New York.  Oceanic  Consulting,  S.A. asserted a cause of action
for breach of contract based upon the allegation that the Company failed to make
payments  pursuant  to a  consulting  agreement.  On  April  13,  2006,  Oceanic
Consulting,  S.A agreed to dismiss the action and  release the Company  from the
claims that were the subject of the action,  any other claims arising out of the
consulting  agreement and any related claims, in exchange for a one-time payment
by the Company. On April 18, 2006, a stipulation of dismissal was filed with the
court and the matter has since been dismissed.

      The  Company  previously  disclosed  that James Paul Brown filed an action
against the Company in the Superior  Court for the State of  California  for the
County of Los  Angeles  on  January  12,  2006 for a single  cause of action for
breach of an alleged oral  consulting  agreement.  The parties  have  executed a
settlement  agreement,  the Company has  performed  its  obligations  under such
agreement,  and a request for dismissal  with  prejudice has been filed with the
court and is awaiting entry by the clerk of the court.









                                    SIGNATURE

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                       Applied DNA Sciences, Inc.
                                       (Registrant)



                                       By:    /s/ James Hayward
                                            --------------------------------
                                       James Hayward
                                       Chief Executive Officer

Date:  April 28, 2006